Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 97,147

Document Document Title
WO/2014/134772A1
Provided are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also provided are pharmaceutical compositions comprising these compounds...  
WO/2014/136305A1
The present invention relates to a morphinan derivative as represented by general formula (I); a tautomer or stereoisomer of said compound; a pharmaceutically acceptable salt thereof; a solvate of the morphinan derivative or of a tautome...  
WO/2014/138484A1
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase ...  
WO/2014/134774A1
Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or tre...  
WO/2014/135529A1
This invention relates to a mixture of at !east three fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), ...  
WO/2014/134776A1
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention i...  
WO/2014/134692A1
The composition of extracts from the genus Hippeastrum and their components is intended for the production of pharmaceuticals and dietary supplements. The composition consists of galanthamine from 40% to 98%, haemanthamine from 0.01 % to...  
WO/2014/136717A1
Provided are: a novel transdermally absorbable pharmaceutical composition which has such characteristic properties that the skin permeability of duloxetine or a pharmaceutically acceptable salt thereof contained in the pharmaceutical com...  
WO/2014/137849A1
The present invention discloses pyridoinolobenz[b,e]azepine derivatives of Formula 1,wherein X is -O-, -S-, -SO-, or -SO2-. Y is a single bond or a double bond. A and B are independently -(CH2)n-; and 'n' varies from 0 to 3. R1 to R9 are...  
WO/2014/136730A1
A method of producing, at a high conversion rate and with good reproducibility, a 3‒[(S)‒7‒bromo‒2‒(2‒oxo‒propylamino)‒5‒pyr idine‒2‒yl‒3H‒1,4‒benzodiazepine‒3‒yl]methyl propionate through the oxidization ...  
WO/2014/136075A1
The present invention relates to new histamine H 3(H 3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/ or hydrates and/or solvates thereo...  
WO/2014/136118A1
An aspect of embodiments of the invention relates to a method for preventing and/or treating post-traumatic stress disorder (PTSD) by administration to a subject an effective amount of melanocortin receptor antagonist. Additional embodim...  
WO/2014/134380A1
One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac...  
WO/2014/133022A1
A compound represented by general formula (I) [wherein R represents a hydrogen atom, a C1-6 alkyl group or the like; R1 represents a C1-6 alkyl group, a C1-6 alkoxy group or the like; R2 represents a halogen atom, a C1-6 alkyl group, a C...  
WO/2014/132430A1
The purpose of the present invention is to provide a ginsenoside composition which is capable of exerting a specifically high efficacy against various symptoms and diseases including unidentified clinical syndrome. The ginsenoside compos...  
WO/2014/132982A1
Ingestion of a composition which contains either Lactobacillus gasseri or both Lactobacillus gasseri and αLA as an active ingredient brings about enhancement of immune responses and a reduction of physical fatigue.  
WO/2014/131855A1
It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to ...  
WO/2014/132210A1
The invention describes antibodies having a high affinity for aggregated forms of a-synuclein and a low affinity for monomeric forms of α-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.  
WO/2014/131825A1
The present invention relates to a multilayer tablet formulation comprising a combination of quetiapine or a pharmaceutically acceptable salt thereof and escitalopram or a pharmaceutically acceptable salt thereof.  
WO/2014/134306A1
The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic ...  
WO/2014/133046A1
There has been a demand for a pharmaceutical composition which is used for a prophylactic and/or therapeutic agent for various diseases associated with PDE10 (for example, mental disorder, neurodegenerative disorder and the like). The pr...  
WO/2014/134349A1
The invention provides for methods of decreasing dual leucine zipper kinase (DLK) stability in a neuron, or decreasing or inhibiting the phosphorylation of certain amino acid residues of DLK, comprising administering to a neuron, or port...  
WO/2014/132215A1
A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37°C, less th...  
WO/2014/134341A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formu...  
WO/2014/131374A1
The invention relates to chemistry and biochemistry applied to the field of medicine, and particularly to a novel method for the prevention and therapeutic treatment of conformational diseases (CD), especially diseases of an amyloid orig...  
WO/2014/132218A1
A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose AUC(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose AUC(2-10) of an immediat...  
WO/2014/134221A1
The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing th...  
WO/2014/128067A1
The invention relates to BET protein-inhibiting, in particular BRD4-inhibiting, bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), to the pharmaceutical agents containing the compo...  
WO/2014/129598A1
A novel use of 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid, which has a protein tyrosine phosphatase 1B (PTP1B) inhibitory effect, Akt activating effect, GSK-3βphosphorylating effect and Aβ1-42-induced τ protein phosp...  
WO/2014/128259A1
The present invention is directed to a pharmaceutical composition or a kit-of-parts and its use in the treatment of burnout syndrome and longevity therapy.  
WO/2014/128223A1
Compounds of formula (I), wherein X, Y, Z, R1-R7, m and n are as defined herein, exhibit 5-HT6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.  
WO/2014/129792A1
The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models w...  
WO/2014/128254A1
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to therapies of neurodegenerative diseases. More specifically, the present invention relates to interleukin-33 (IL-33), a frag...  
WO/2014/130581A1
Provided herein are methods of treatment of migraine headaches comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.  
WO/2014/128585A1
The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined 5 herein. The compounds of formula I are useful as inhibitors of PDE4 for the treatment...  
WO/2014/129411A1
[Problem] The purpose of the present invention is to provide a pharmaceutical composition containing an antibacterial agent, which is effective in elucidating one cause of dementia, and in treatment thereof. [Solution] The present invent...  
WO/2014/128882A1
A medicine that comprises a compound, or a pharmaceutically acceptable salt thereof, for treating depression accompanied by intrusive cognitive emotion, i.e., so-called anxiety depression, said compound having an anti-noradrenaline effec...  
WO/2014/128486A1
Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases ΙΚΚε and/or TBK-1 in which one of V and W is N, and the other of V and W is C-H; ...  
WO/2014/130894A1
This invention provides compounds, methods and compositions for the treatment of inflammatory diseases, comprising the timely administration of a provided compound, which has a structure related to an endogenously formed lipid mediator. ...  
WO/2014/129990A1
This invention relates to novel (±)1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions.  
WO/2014/129744A1
The present invention relates to: a novel four-membered cyclic nitrogen compound capable of being used as an agent for treating or preventing depression, mental disorders, premature ejaculation or neuropathic pain by highly preventing th...  
WO/2014/129989A1
This invention is related with the conversion of xenobiotics to potent ACHE and BCHE inhibitors that have activity comparable to the current ACHE and BCHE inhibitor drugs (i.e., donepezil, rivastigmine, and galantamine).  
WO/2014/127458A1
The current application relates to a liquid pharmaceutical composition for intraoral transmucosal administration of a benzodiazepine drug to a mammal. The composition comprises a physiologically acceptable hydrophobic phase, an eutectic ...  
WO/2014/127735A1
The present invention relates to solid forms of trelagliptin, a preparation method therefor and applications thereof, and relates specifically to six new solid forms of the dipeptidyl peptidase-4 inhibitor trelagliptin and preparation me...  
WO/2014/130258A1
The present disclosure is generally directed to compounds which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKl.  
WO/2014/127459A1
The current application relates to a liquid pharmaceutical composition for intiaoral tiansmucosal admmistiation of a benzodiazepine drag to a mammal The composition comprises a physiologically acceptable hydrophobic phase, a eutectic mix...  
WO/2014/125256A1
Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a...  
WO/2014/126596A1
The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R1 is CH2 or C2H4; R2 is H or -OR4 where R4 is H or aryl; and R3a and R3b ar...  
WO/2014/127360A1
Disclosed herein are compounds useful for detecting oxidants in a living cell, in a multicellular organism, or in a cell-free sample. In particular, disclosed herein are bioluminescent reporter compounds, and more particularly, fluorinat...  
WO/2014/127042A1
In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears t...  

Matches 201 - 250 out of 97,147